糖尿病性網膜症の世界市場レポート 2025年

糖尿病性網膜症市場規模は、今後数年間で力強い成長が見込まれます。2029年には125億6,000万米ドルに成長し、CAGRは7.8％となります。予測期間の成長は、個別化医療アプローチ、遠隔医療サービスの拡大、新規治療介入の開発、ポイントオブケア検査の採用、遠隔患者モニタリングに起因します。予測期間の主な動向としては、治療における精密医療、早期発見と予防への注目の高まり、遠隔眼科サービスの成長、遺伝子治療研究の増加、網膜画像技術の継続的進歩などが挙げられます。

糖尿病有病率の増加は、今後の糖尿病性網膜症市場の成長を牽引すると予想されます。糖尿病は、高い血糖値を特徴とする慢性代謝性疾患です。この糖尿病有病率の上昇は、過体重、肥満、遺伝、運動不足などの要因に大きく影響されています。高血糖は、光を感知し、目の奥の神経を通して脳に信号を送る役割を担う目の部分である網膜を損傷する可能性があります。例えば、英国の政府機関であるOffice for Health Improvement and Disparitiesの報告によると、2022年3月から2023年3月にかけて、1型糖尿病患者が推奨される8つのケアプロセスをすべて受けている割合は22％増加し、2型糖尿病患者は21％増加しました。さらに、HbA1cの目標値を達成した人の割合は37.9%に達し、全国糖尿病監査が記録した中で最高となった。このように、糖尿病有病率の増加は、糖尿病性網膜症市場の拡大に大きく寄与しています。

高齢者の割合の増加が、今後の糖尿病性網膜症市場の成長を牽引すると予測されています。高齢化とは、年齢が進行し、老化の影響を経験している人々を指します。このプロセスは、糖尿病などの慢性疾患への感受性の高まりと関連しており、糖尿病性網膜症に脆弱な人口を増加させ、リスクを高めます。例えば、スイスに本部を置く世界保健機関（WHO）の報告によると、2050年までに高齢者の80％が低・中所得国に住むようになると予想されています。2030年には、世界の6人に1人が60歳以上の高齢者となり、この年齢層の人口比率が大幅に増加します。さらに、60歳以上の世界人口は2050年までに倍増し、21億人に達すると予測されています。したがって、高齢化比率の増加が糖尿病性網膜症市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界糖尿病性網膜症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の糖尿病性網膜症市場：成長率分析
• 世界の糖尿病性網膜症市場の実績：規模と成長, 2019-2024
• 世界の糖尿病性網膜症市場の予測：規模と成長, 2024-2029, 2034F
• 世界糖尿病性網膜症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の糖尿病性網膜症市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 増殖性糖尿病性網膜症
• 非増殖性糖尿病性網膜症
• 世界の糖尿病性網膜症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗VEGF薬
• 眼内ステロイド注射
• レーザー光凝固術
• 硝子体網膜手術
• 世界の糖尿病性網膜症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来手術センター
• その他のエンドユーザー
• 世界の糖尿病性網膜症市場増殖型糖尿病性網膜症（PDR）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 新生血管
• 硝子体出血
• 牽引性網膜剥離
• 世界の糖尿病性網膜症市場、非増殖性糖尿病性網膜症（NPDR）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽度のNPDR
• 中程度のNPDR
• 重度のNPDR

第7章 地域別・国別分析

• 世界の糖尿病性網膜症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の糖尿病性網膜症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 糖尿病性網膜症市場：競合情勢
• 糖尿病性網膜症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F-Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Ellex Medical Lasers Ltd.
• Abbott Laboratories Inc.
• Regeneron Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Icon Bioscience Inc.
• Allergan plc.
• Genentech Inc.
• Aurobindo Pharma
• Santen Pharmaceutical Co. Ltd.
• Carl Zeiss Meditec AG
• Valeant Pharmaceuticals International Inc.
• Lumenis Ltd.
• Optos Plc.
• Quantel Medical SAS
• NIDEK Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 糖尿病性網膜症市場2029：新たな機会を提供する国
• 糖尿病性網膜症市場2029：新たな機会を提供するセグメント
• 糖尿病性網膜症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Diabetic retinopathy is a complication of diabetes that impacts the retina, the light-sensitive tissue at the back of the eye. It occurs due to damage to the blood vessels caused by prolonged high blood sugar levels. If not properly managed, this condition can lead to vision loss and even blindness, underscoring the importance of regular eye examinations for early detection and treatment.

The primary types of diabetic retinopathy include proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. Proliferative diabetic retinopathy represents the advanced stage characterized by the emergence of abnormal new blood vessels on the surface of the retina. Various treatment modalities, such as anti-VEGF drugs, intraocular steroid injections, laser photocoagulation, and vitreoretinal surgery, are employed in settings such as hospitals, ambulatory surgical centers, and other healthcare facilities.

The diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides diabetic retinopathy market statistics, including diabetic retinopathy industry global market size, regional shares, competitors with a diabetic retinopathy market share, detailed diabetic retinopathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic retinopathy industry. This diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic retinopathy market size has grown strongly in recent years. It will grow from $8.61 billion in 2024 to $9.29 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to aging population, increasing prevalence of diabetes, growing awareness about diabetic retinopathy, improved healthcare infrastructure, rising healthcare expenditure

The diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $12.56 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to personalized medicine approaches, expansion of telemedicine services, development of novel therapeutic interventions, adoption of point-of-care testing, remote patient monitoring. Major trends in the forecast period include precision medicine in diabetic retinopathy treatment, increased focus on early detection and prevention, teleophthalmology services growth, rise in gene therapy research, continuous advancements in retinal imaging technology.

The increasing prevalence of diabetes is expected to drive the growth of the diabetic retinopathy market in the future. Diabetes is a chronic metabolic disease characterized by high blood glucose levels. This rise in diabetes prevalence is largely influenced by factors such as overweight, obesity, genetics, and physical inactivity. High blood sugar levels can damage the retina, the part of the eye responsible for detecting light and sending signals to the brain through a nerve at the back of the eye. For example, a report from the Office for Health Improvement and Disparities, a UK government department, indicated that from March 2022 to March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while type 2 diabetes saw a 21% rise. Additionally, the proportion of people achieving target HbA1c levels reached 37.9%, the highest recorded by the National Diabetes Audit. Thus, the growing prevalence of diabetes is significantly contributing to the expansion of the diabetic retinopathy market.

The increasing proportion of aging individuals is anticipated to drive the growth of the diabetic retinopathy market in the future. Aging individuals refer to those who are progressing in age and experiencing the effects of aging. This process is associated with a heightened susceptibility to chronic conditions, such as diabetes, which raises the risk and enlarges the population vulnerable to diabetic retinopathy. For instance, a report from the World Health Organization, a Switzerland-based agency, indicated that by 2050, 80% of older individuals are expected to live in low- and middle-income countries. By 2030, one in six people worldwide will be aged 60 years or older, significantly increasing the proportion of the population in this age group. Furthermore, the global population of individuals aged 60 and older is projected to double by 2050, reaching 2.1 billion. Therefore, the growing proportion of aging individuals is contributing to the expansion of the diabetic retinopathy market.

Technological advancements represent a prominent trend gaining traction in the diabetic retinopathy market. Major companies within this market are embracing innovative technologies to maintain their competitive standing. For instance, in July 2022, Baxter International Inc., a US-based healthcare company, introduced the Welch Allyn RetinaVue 100 Imager PRO in South Korea. These cutting-edge technologies aim to facilitate the detection of diabetic retinopathy in primary care settings, streamlining the process for annual diabetic retinal exams (DREs) during routine primary care visits and enhancing patient compliance.

Companies operating in the diabetic retinopathy market are strategically entering partnerships to enhance their market profitability. Collaborations in the context of diabetic retinopathy involve coordinated efforts among diverse stakeholders, including healthcare providers, researchers, pharmaceutical companies, and advocacy groups, to address challenges associated with diabetic retinopathy. For example, in October 2023, AEYE Health, a US-based provider of AI-based diagnostics for retinal imaging, joined forces with Topcon Screen, a Japan-based diabetic screening platform. Their collaboration aims to offer point-of-care screening for diabetic retinopathy using artificial intelligence, ensuring swift and precise results. This approach enables primary care clinicians to conduct diabetic retinopathy screenings directly in their clinics, reducing non-compliance risks and addressing care gaps associated with diabetic retinopathy screening through immediate and accurate assessments at the point of care.

In January 2022, Meteda, a US-based healthcare technology company, completed the acquisition of Retmarker SA for an undisclosed amount. Through this strategic move, Meteda seeks to broaden its access to periodic screening for diabetic retinopathy, utilize AI to address various diabetes-related issues, and strengthen its position in the EMEA region. Retmarker SA, based in Portugal, is an AI technology company specializing in ophthalmology, particularly focusing on retinal conditions such as diabetic retinopathy.

Major companies operating in the diabetic retinopathy market include Pfizer Inc., F-Hoffmann-La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, Ellex Medical Lasers Ltd., Abbott Laboratories Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Icon Bioscience Inc., Allergan plc., Genentech Inc., Aurobindo Pharma, Santen Pharmaceutical Co. Ltd., Carl Zeiss Meditec AG, Valeant Pharmaceuticals International Inc., Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co. Ltd., IRIDEX Corporation, Alimera Science Inc., Kowa Company Ltd., Ocular Therapeutix Inc., Aerpio Pharmaceuticals Inc., Kodiak Sciences Inc., Oxurion NV, Graybug Vision Inc., Ampio Pharmaceuticals Inc.

North America was the largest region in the diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the diabetic retinopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic retinopathy market includes revenues earned by entities by providing ophthalmologic examination, eye management and retinal imaging and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Retinopathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic retinopathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic retinopathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diabetic retinopathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Proliferative Diabetic Retinopathy; Non-Proliferative Diabetic Retinopathy
• 2) By Treatment: Anti-VEGF Drugs; Intraocular Steroid Injection; Laser Photocoagulation; Vitreoretinal Surgery
• 3) By End-User: Hospitals; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Proliferative Diabetic Retinopathy (PDR): Neovascularization; Vitreous Hemorrhage; Tractional Retinal Detachment
• 2) By Non-Proliferative Diabetic Retinopathy (NPDR): Mild NPDR; Moderate NPDR; Severe NPDR
• Companies Mentioned: Pfizer Inc.; F-Hoffmann-La Roche Ltd.; Abbvie Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Retinopathy Market Characteristics

3. Diabetic Retinopathy Market Trends And Strategies

4. Diabetic Retinopathy Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Diabetic Retinopathy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Retinopathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Retinopathy Market Growth Rate Analysis
• 5.4. Global Diabetic Retinopathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Retinopathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Retinopathy Total Addressable Market (TAM)

6. Diabetic Retinopathy Market Segmentation

• 6.1. Global Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proliferative Diabetic Retinopathy
• Non-Proliferative Diabetic Retinopathy
• 6.2. Global Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-VEGF Drugs
• Intraocular Steroid Injection
• Laser Photocoagulation
• Vitreoretinal Surgery
• 6.3. Global Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Other End Users
• 6.4. Global Diabetic Retinopathy Market, Sub-Segmentation Of Proliferative Diabetic Retinopathy (PDR), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neovascularization
• Vitreous Hemorrhage
• Tractional Retinal Detachment
• 6.5. Global Diabetic Retinopathy Market, Sub-Segmentation Of Non-Proliferative Diabetic Retinopathy (NPDR), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild NPDR
• Moderate NPDR
• Severe NPDR

7. Diabetic Retinopathy Market Regional And Country Analysis

• 7.1. Global Diabetic Retinopathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Retinopathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Retinopathy Market

• 8.1. Asia-Pacific Diabetic Retinopathy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Retinopathy Market

• 9.1. China Diabetic Retinopathy Market Overview
• 9.2. China Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Retinopathy Market

• 10.1. India Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Retinopathy Market

• 11.1. Japan Diabetic Retinopathy Market Overview
• 11.2. Japan Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Retinopathy Market

• 12.1. Australia Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Retinopathy Market

• 13.1. Indonesia Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Retinopathy Market

• 14.1. South Korea Diabetic Retinopathy Market Overview
• 14.2. South Korea Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Retinopathy Market

• 15.1. Western Europe Diabetic Retinopathy Market Overview
• 15.2. Western Europe Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Retinopathy Market

• 16.1. UK Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Retinopathy Market

• 17.1. Germany Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Retinopathy Market

• 18.1. France Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Retinopathy Market

• 19.1. Italy Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Retinopathy Market

• 20.1. Spain Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Retinopathy Market

• 21.1. Eastern Europe Diabetic Retinopathy Market Overview
• 21.2. Eastern Europe Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Retinopathy Market

• 22.1. Russia Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Retinopathy Market

• 23.1. North America Diabetic Retinopathy Market Overview
• 23.2. North America Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Retinopathy Market

• 24.1. USA Diabetic Retinopathy Market Overview
• 24.2. USA Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Retinopathy Market

• 25.1. Canada Diabetic Retinopathy Market Overview
• 25.2. Canada Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Retinopathy Market

• 26.1. South America Diabetic Retinopathy Market Overview
• 26.2. South America Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Retinopathy Market

• 27.1. Brazil Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Retinopathy Market

• 28.1. Middle East Diabetic Retinopathy Market Overview
• 28.2. Middle East Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Retinopathy Market

• 29.1. Africa Diabetic Retinopathy Market Overview
• 29.2. Africa Diabetic Retinopathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Retinopathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Retinopathy Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Retinopathy Market Competitive Landscape
• 30.2. Diabetic Retinopathy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F-Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Retinopathy Market Other Major And Innovative Companies

• 31.1. Ellex Medical Lasers Ltd.
• 31.2. Abbott Laboratories Inc.
• 31.3. Regeneron Pharmaceuticals Inc.
• 31.4. Bausch Health Companies Inc.
• 31.5. Icon Bioscience Inc.
• 31.6. Allergan plc.
• 31.7. Genentech Inc.
• 31.8. Aurobindo Pharma
• 31.9. Santen Pharmaceutical Co. Ltd.
• 31.10. Carl Zeiss Meditec AG
• 31.11. Valeant Pharmaceuticals International Inc.
• 31.12. Lumenis Ltd.
• 31.13. Optos Plc.
• 31.14. Quantel Medical SAS
• 31.15. NIDEK Co. Ltd.

32. Global Diabetic Retinopathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Retinopathy Market

34. Recent Developments In The Diabetic Retinopathy Market

35. Diabetic Retinopathy Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Retinopathy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Retinopathy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Retinopathy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer